Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on August 9, 2004

Circulation. 2004
Published online before print August 9, 2004, doi: 10.1161/01.CIR.0000139337.56084.30
A more recent version of this article appeared on August 24, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/8/940    most recent
01.CIR.0000139337.56084.30v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farb, A.
Right arrow Articles by Virmani, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farb, A.
Right arrow Articles by Virmani, R.
Related Collections
Right arrow Restenosis
Right arrow Catheter-based coronary interventions: stents
Right arrow Coronary circulation

Submitted on March 5, 2004
Revised on April 29, 2004
Accepted on May 3, 2004

Extracellular Matrix Changes in Stented Human Coronary Arteries

Andrew Farb MD, Frank D. Kolodgie PhD, Jin-Yong Hwang MD, PhD, Allen P. Burke MD, Kirubel Tefera BSc, Deena K. Weber MS, Thomas N. Wight PhD, and Renu Virmani MD*

From the Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, DC (A.F., F.D.K., A.P.B., K.T., D.K.W., R.V.); the Hope Heart Institute, Seattle, Wash (T.N.W., J.-Y.H.); and Gyeongsang National University, Jinju, Korea (J.-Y.H.).

* To whom correspondence should be addressed. E-mail: Virmani{at}afip.osd.mil.

Background--Restenosis after stenting occurs secondary to the accumulation of smooth muscle cells (SMCs) and extracellular matrix (ECM), with the ECM accounting for >50% of the neointimal volume. The composition of the in-stent ECM has not been well characterized in humans.

Methods and Results--Postmortem human coronary arteries (n=45) containing stents underwent histological assessment of neointimal proteoglycans, hyaluronan, collagen (types I and III), SMCs, and CD44 (a cell surface receptor for hyaluronan). The mean duration of stent implantation was 18.7 months; stents in place ≥3 to <9 months (n=17) were assigned to group 1, stents ≥9 to <18 months old (n=19) to group 2, and stents ≥18 months old (n=9) to group 3. In groups 1 and 2, neointimal versican and hyaluronan staining was strongly positive, colocalized with {alpha}-actin-positive SMCs, and was greater in intensity compared with group 3. Conversely, decorin staining was greatest in group 3. The neointima of both group 1 and 2 stents was rich in type III collagen, with reduced staining in group 3. Type I collagen staining was weakest in group 1 stents, with progressively stronger staining in groups 2 and 3. SMC density and stent stenosis were significantly reduced in group 3 stents compared with groups 1 and 2. CD44 staining colocalized with macrophages and was associated with increased neointimal thickness.

Conclusions--The ECM within human coronary stents resembles a wound that is not fully healed until 18 months after deployment, followed by neointimal retraction. ECM contraction may be a target for therapies aimed at stent restenosis prevention.


Key words: atherosclerosis • pathology • restenosis • stents




This article has been cited by other articles:


Home page
J. Histochem. Cytochem.Home page
R. D. Kenagy, S.-K. Min, A. W. Clowes, and J. D. Sandy
Cell Death-associated ADAMTS4 and Versican Degradation in Vascular Tissue
J. Histochem. Cytochem., September 1, 2009; 57(9): 889 - 897.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
B. S. Fleenor and D. K. Bowles
Exercise training decreases the size and alters the composition of the neointima in a porcine model of percutaneous transluminal coronary angioplasty (PTCA)
J Appl Physiol, September 1, 2009; 107(3): 937 - 945.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Tsai, S. T. Hollenbeck, E. J. Ryer, R. Edlin, D. Yamanouchi, R. Kundi, C. Wang, B. Liu, and K. C. Kent
TGF-{beta} through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation
Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H540 - H549.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol ImgHome page
G. Nakazawa, M. Vorpahl, A. V. Finn, J. Narula, and R. Virmani
One step forward and two steps back with drug-eluting-stents from preventing restenosis to causing late thrombosis and nouveau atherosclerosis.
J. Am. Coll. Cardiol. Img., May 1, 2009; 2(5): 625 - 628.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Y. Lee, A. S. Martin, P. K. Mehta, A. E. Dikalova, A. M. Garrido, S. R. Datla, E. Lyons, K.-H. Krause, B. Banfi, J. D. Lambeth, et al.
Mechanisms of Vascular Smooth Muscle NADPH Oxidase 1 (Nox1) Contribution to Injury-Induced Neointimal Formation
Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 480 - 487.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. V. Finn, G. Nakazawa, M. Joner, F. D. Kolodgie, E. K. Mont, H. K. Gold, and R. Virmani
Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing
Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1500 - 1510.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
W. J. Gomes and E. Buffolo
Coronary stenting and inflammation: implications for further surgical and medical treatment.
Ann. Thorac. Surg., May 1, 2006; 81(5): 1918 - 1925.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
V. da Cunha, B. Martin-McNulty, J. Vincelette, L. Zhang, J. C. Rutledge, D. W. Wilson, R. Vergona, M. E. Sullivan, and Y.-X. Wang
Interaction between mild hypercholesterolemia, HDL-cholesterol levels, and angiotensin II in intimal hyperplasia in mice
J. Lipid Res., March 1, 2006; 47(3): 476 - 483.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Aoki, A. Colombo, D. Dudek, A. P. Banning, J. Drzewiecki, K. Zmudka, F. Schiele, M. E. Russell, J. Koglin, P. W. Serruys, et al.
Peristent Remodeling and Neointimal Suppression 2 Years After Polymer-Based, Paclitaxel-Eluting Stent Implantation: Insights From Serial Intravascular Ultrasound Analysis in the TAXUS II Study
Circulation, December 20, 2005; 112(25): 3876 - 3883.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J.W. Fischer
Dexamethasone: Effects on neointimal hyperplasia and vessel integrity
Cardiovasc Res, December 1, 2005; 68(3): 350 - 352.
[Full Text] [PDF]


Home page
CirculationHome page
M. A. Costa and D. I. Simon
Molecular Basis of Restenosis and Drug-Eluting Stents
Circulation, May 3, 2005; 111(17): 2257 - 2273.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Rahmani, J. T. Read, J. M. Carthy, P. C. McDonald, B. W. Wong, M. Esfandiarei, X. Si, Z. Luo, H. Luo, P. S. Rennie, et al.
Regulation of the Versican Promoter by the {beta}-Catenin-T-cell Factor Complex in Vascular Smooth Muscle Cells
J. Biol. Chem., April 1, 2005; 280(13): 13019 - 13028.
[Abstract] [Full Text] [PDF]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
A. W. Clowes
Circulating Monocytes and In-Stent Neointima After Coronary Stent Implantation
Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2005; 17(1): 60-1 - 62.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
K. Yamamoto, K. Onoda, Y. Sawada, K. Fujinaga, K. Imanaka-Yoshida, H. Shimpo, T. Yoshida, and I. Yada
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice
Cardiovasc Res, February 15, 2005; 65(3): 737 - 742.
[Abstract] [Full Text] [PDF]